Distinct Roles of PD-L1 and PD-L2 in Primary Mediastinal Large B-Cell Lymphoma: Implications for Immune Therapeutics
Highlight
Primary mediastinal large B-cell lymphoma (PMBCL) features frequent 9p24.1 genetic alterations driving overexpression of PD-1 ligands PD-L1 and PD-L2. PD-L1 predominantly suppresses Th1 immune signaling and predicts response to PD-1 blockade, while PD-L2 maintains B-cell lineage transcriptional programs and associates with distinct treatment responses. Combined targeting of both ligands enhances Th1 activation and modulates lymphoma transcriptional states.
Study Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.